Comparison of Online-Onboard Adaptive Intensity-Modulated Radiation Therapy or Volumetric-Modulated Arc Radiotherapy With Image-Guided Radiotherapy for Patients With Gynecologic Tumors in Dependence on Fractionation and the Planning Target Volume Margin
Maja Guberina, Alina Santiago Garcia, Aymane Khouya, Christoph Pöttgen, Kostyantyn Holubyev, Toke Printz Ringbaek, Manfred Lachmuth, Yasemin Alberti, Christian Hoffmann, Julian Hlouschek, Thomas Gauler, Wolfgang Lübcke, Frank Indenkämpen, Martin Stuschke, Nika Guberina, Maja Guberina, Alina Santiago Garcia, Aymane Khouya, Christoph Pöttgen, Kostyantyn Holubyev, Toke Printz Ringbaek, Manfred Lachmuth, Yasemin Alberti, Christian Hoffmann, Julian Hlouschek, Thomas Gauler, Wolfgang Lübcke, Frank Indenkämpen, Martin Stuschke, Nika Guberina
Abstract
Importance: Patients with newly diagnosed locally advanced cervical carcinomas or recurrences after surgery undergoing radiochemotherapy whose tumor is unsuited for a brachytherapy boost need high-dose percutaneous radiotherapy with small margins to compensate for clinical target volume deformations and set-up errors. Cone-beam computed tomography-based online adaptive radiotherapy (ART) has the potential to reduce planning target volume (PTV) margins below 5 mm for these tumors.
Objective: To compare online ART technologies with image-guided radiotherapy (IGRT) for gynecologic tumors.
Design, setting, and participants: This comparative effectiveness study comprised all 7 consecutive patients with gynecologic tumors who were treated with ART with artificial intelligence segmentation from January to May 2022 at the West German Cancer Center. All adapted treatment plans were reviewed for the new scenario of organs at risk and target volume. Dose distributions of adapted and scheduled plans optimized on the initial planning computed tomography scan were compared.
Exposure: Online ART for gynecologic tumors.
Main outcomes and measures: Target dose coverage with ART compared with IGRT for PTV margins of 5 mm or less in terms of the generalized equivalent uniform dose (gEUD) without increasing the gEUD for the organs at risk (bladder and rectum).
Results: The first 10 treatment series among 7 patients (mean [SD] age, 65.7 [16.5] years) with gynecologic tumors from a prospective observational trial performed with ART were compared with IGRT. For a clinical PTV margin of 5 mm, IGRT was associated with a median gEUD decrease in the interfractional clinical target volume of -1.5% (90% CI, -31.8% to 2.9%) for all fractions in comparison with the planned dose distribution. Online ART was associated with a decrease of -0.02% (90% CI, -3.2% to 1.5%), which was less than the decrease with IGRT (P < .001). This was not associated with an increase in the gEUD for the bladder or rectum. For a PTV margin of 0 mm, the median gEUD deviation with IGRT was -13.1% (90% CI, -47.9% to 1.6%) compared with 0.1% (90% CI, -2.3% to 6.6%) with ART (P < .001). The benefit associated with ART was larger for a PTV margin of 0 mm than of 5 mm (P = .004) due to spreading of the cold spot at the clinical target volume margin from fraction to fraction with a median SD of 2.4 cm (90% CI, 1.9-3.4 cm) for all patients.
Conclusions and relevance: This study suggests that ART is associated with an improvement in the percentage deviation of gEUD for the interfractional clinical target volume compared with IGRT. As the gain of ART depends on fractionation and PTV margin, a strategy is proposed here to switch from IGRT to ART, if the delivered gEUD distribution becomes unfavorable in comparison with the expected distribution during the course of treatment.
Conflict of interest statement
Conflict of Interest Disclosures: Dr Stuschke reported receiving a research grant (to institution) from AstraZeneca; and serving on the advisory boards for AstraZeneca, Bristol Myers Squibb, Janssen-Cilag, and Sanofi/Aventis outside the submitted work. No other disclosures were reported.
Figures
References
- da Costa SCS, Bonadio RC, Gabrielli FCG, et al. . Neoadjuvant chemotherapy with cisplatin and gemcitabine followed by chemoradiation versus chemoradiation for locally advanced cervical cancer: a randomized phase II trial. J Clin Oncol. 2019;37(33):3124-3131. doi:10.1200/JCO.19.00674
- Scorsetti M, Navarria P, Mancosu P, et al. . Large volume unresectable locally advanced non-small cell lung cancer: acute toxicity and initial outcome results with rapid arc. Radiat Oncol. 2010;5:94. doi:10.1186/1748-717X-5-94
- Smaniotto D, D’Agostino G, Luzi S, et al. . Concurrent 5-fluorouracil, mitomycin C and radiation with or without brachytherapy in recurrent cervical cancer: a scoring system to predict clinical response and outcome. Tumori. 2005;91(4):295-301. doi:10.1177/030089160509100402
- Maneo A, Landoni F, Cormio G, et al. . Concurrent carboplatin/5-fluorouracil and radiotherapy for recurrent cervical carcinoma. Ann Oncol. 1999;10(7):803-807. doi:10.1023/A:1008356010556
- Ito K, Kito S, Nakajima Y, et al. . Determining the recommended dose of stereotactic body radiotherapy boost in patients with cervical cancer who are unsuitable for intracavitary brachytherapy: a phase I dose-escalation study. Jpn J Clin Oncol. 2019;49(9):856-861. doi:10.1093/jjco/hyz074
- Lőcsei Z, Sebestyén K, Sebestyén Z, et al. . IMAT-IGRT treatment with simultaneous integrated boost as dose escalation for patients with cervical cancer: a single institution, prospective pilot study. Pathol Oncol Res. 2021;27:608446. doi:10.3389/pore.2021.608446
- Mazzola R, Ricchetti F, Fiorentino A, et al. . Weekly cisplatin and volumetric-modulated arc therapy with simultaneous integrated boost for radical treatment of advanced cervical cancer in elderly patients: feasibility and clinical preliminary results. Technol Cancer Res Treat. 2017;16(3):310-315. doi:10.1177/1533034616655055
- Albuquerque K, Tumati V, Lea J, et al. . A phase ii trial of stereotactic ablative radiation therapy as a boost for locally advanced cervical cancer. Int J Radiat Oncol Biol Phys. 2020;106(3):464-471. doi:10.1016/j.ijrobp.2019.10.042
- Morgenthaler J, Köhler C, Budach V, et al. . Long-term results of robotic radiosurgery for non brachytherapy patients with cervical cancer. Strahlenther Onkol. 2021;197(6):474-486. doi:10.1007/s00066-020-01685-x
- Campitelli M, Lazzari R, Piccolo F, et al. . Brachytherapy or external beam radiotherapy as a boost in locally advanced cervical cancer: a gynaecology study group in the Italian Association of Radiation and Clinical Oncology (AIRO) review. [review]. Int J Gynecol Cancer. 2021;31(9):1278-1286. doi:10.1136/ijgc-2020-002310
- Archambault Y, Boylan C, Bullock D, et al. . Making online adaptive radiotherapy possible using artificial intelligence and machine learning for efficient daily re-planning. Med Phys Int J. 2020;8(2):77-86. Accessed March 2, 2023.
- Corradini S, Alongi F, Andratschke N, et al. . ESTRO-ACROP recommendations on the clinical implementation of hybrid MR-linac systems in radiation oncology. Radiother Oncol. 2021;159:146-154. doi:10.1016/j.radonc.2021.03.025
- Sibolt P, Andersson LM, Calmels L, et al. . Clinical implementation of artificial intelligence–driven cone-beam computed tomography–guided online adaptive radiotherapy in the pelvic region. Phys Imaging Radiat Oncol. 2020;17:1-7.
- Breto AL, Spieler B, Zavala-Romero O, et al. . Deep learning for per-fraction automatic segmentation of gross tumor volume (GTV) and organs at risk (OARs) in adaptive radiotherapy of cervical cancer. Front Oncol. 2022;12:854349. doi:10.3389/fonc.2022.854349
- Chapman JW, Lam D, Cai B, Hugo GD. Robustness and reproducibility of an artificial intelligence–assisted online segmentation and adaptive planning process for online adaptive radiation therapy. J Appl Clin Med Phys. 2022;23(8):e13702. doi:10.1002/acm2.13702
- Berger ML, Mamdani M, Atkins D, Johnson ML. Good research practices for comparative effectiveness research: defining, reporting and interpreting nonrandomized studies of treatment effects using secondary data sources: the ISPOR Good Research Practices for Retrospective Database Analysis Task Force Report—part I. Value Health. 2009;12(8):1044-1052. doi:10.1111/j.1524-4733.2009.00600.x
- Levegrün S, Pöttgen C, Xydis K, Guberina M, Abu Jawad J, Stuschke M. Spatial and dosimetric evaluation of residual distortions of prostate and seminal vesicle bed after image-guided definitive and postoperative radiotherapy of prostate cancer with endorectal balloon. J Appl Clin Med Phys. 2021;22(1):226-241. doi:10.1002/acm2.13138
- Mahantshetty U, Poetter R, Beriwal S, et al. . IBS-GEC ESTRO-ABS recommendations for CT based contouring in image guided adaptive brachytherapy for cervical cancer. Radiother Oncol. 2021;160:273-284. doi:10.1016/j.radonc.2021.05.010
- World Medical Association . World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA. 2013;310(20):2191-2194. doi:10.1001/jama.2013.281053
- Pötter R, Tanderup K, Schmid MP, et al; EMBRACE Collaborative Group. MRI-guided adaptive brachytherapy in locally advanced cervical cancer (EMBRACE-I): a multicentre prospective cohort study. Lancet Oncol. 2021;22(4):538-547. doi:10.1016/S1470-2045(20)30753-1
Source: PubMed